We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Western Europe,Eastern Europe,Asia,Middle East
Monthly Production Capacity: 58 million tablets
Packaging Information: --
Delivery Lead Time: 1 month
Sample Provided: no
Payment Terms: T/T
Pioglitazone Hydrochloride Tablets
ANDA Review
Note: the content below does not include all the information needed to use Pioglitazone Hydrochloride Tablets safely and effectively.
INDICATIONS AND USAGE
Pioglitazone Hydrochloride Tablets is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
Important Limitations of Use:
Not for treatment of type 1 diabetes or diabetic ketoacidosis
DOSAGE AND ADMINISTRATION
Initiate the drug at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure.
If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily.
Obtain liver tests before starting the drug. If abnormal, use caution when treating with the drug, investigate the recommended in patients without liver disease.
Two years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
